TheraRadar
← Back
Data updated: May 24, 2026

GE HEALTHCARE

Specialty
NeurologyCardiovascularInfectious Disease Execution: Good

GE HEALTHCARE is a specialty pharmaceutical company focused on Neurology, Cardiovascular, Infectious Disease. Key products include VIZAMYL.

1951
Since
57
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
16 Small Molecules
Novel Drugs (2020):
1 Novel Approvals

GE HEALTHCARE at a Glance

  • Fast trial execution (13 months median completion)

Upcoming FDA Decisions

Full Calendar →
Aug 19, 2026 — Garetosmab
Aug 23, 2026 — DTX401 (pariglasgene brecaparvovec)
Oct 17, 2026 — Phentolamine ophthalmic solution 0.75%
+2 more dates (Pro)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

CLARISCAN
Other

Disruption of the Blood Brain Barrier

Approved 2019
VIZAMYL
CNS

Alzheimer's Disease

Amyloid beta Approved 2013
CERIANNA
Oncology

Breast Cancer

ER Approved 2020

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

No recent approvals

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Neurology 33%
1 drugs Phase 3: 4 Phase 2: 3 Phase 1: 1
Cardiovascular 21%
1 drugs Phase 3: 1 Phase 2: 3 Phase 1: 3
Infectious Disease 20%
3 drugs
Oncology 18%
1 drugs Phase 2: 3 Phase 1: 4
Respiratory 8%
1 drugs Phase 1: 1

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

5
Phase 3
9
Phase 2
9
Phase 1

Phase 3 Readout Calendar Pro

2 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q4 2027
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL
Known or Highly Suspected Central Nervous System (CNS) Lesion
Estimated · fresh NCT07472491
Q2 2029
GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT)
Colorectal Cancer
Estimated · aging NCT07219238

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CLARISCAN leads revenue
  • • 3 key drugs tracked

Trial Catalysts

  • • Neurology pipeline focus
  • • 2 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 9/11 completed
  • • Speed: 13 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges